While the drop in Ultragenyx stock certainly provides a lower entry point for new investors, the more prudent choice right ...

A dedicated bioimaging function at GSK has shown how integrated microscopy and analytics can deliver quantitative evidence ...

Historically, people with amyotrophic lateral sclerosis (ALS) experience a relentless decline in neurological function that ...

In September 2025, AusperBio completed participant enrolment in two Phase II studies evaluating AHB-137 for the functional cure of CHB. "AusperBio concludes enrolment in Phase III AUSHINE trial" was ...

AusperBio completes patient enrollment in phase III AUSHINE study of AHB-137 for chronic hepatitis B: San Francisco Tuesday, December 23, 2025, 15:00 Hrs [IST] AusperBio Therapeut ...

Use this brand-new eBook from Cytiva to learn more about the oligonucleotide market as a whole and about the full workflow solutions available today. We hope you enjoy it!

PLX READ THE FULL PLX RESEARCH REPORT Protalix BioTherapeutics, Inc. (NYSE:PLX) announced a collaboration with the Germany-based Secarna Pharmaceuticals to develop novel antisense oligonucleotide (ASO ...

Alnylam's $250 million investment will enhance its Norton, Massachusetts facility with an enzymatic ligation platform to meet ...

The Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide chemistries ...

The first part of an end-of-the-year review of LCGC International’s editorial coverage of HPLC 2025, which took place in Bruges from 19–23 June 2025 .